Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Change in Management
Re-appointment of Mr. Fredun Medhora as the Managing Director of the Company for a further term of five years wef 15.10.2023 to 14.10.202808-11-2023
08-11-2023
Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for OUTCOME OF BOARD MEETING HELD ON 08TH NOVEMBER,2023
1. In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirement) Requirements 2015 the un-audited financials for the quarter and half year ended 30th September,2023 along with limited review report as issued by M/s. RH Nisar & Co. Statutory Auditors of the Company. 2. Re-appointment of Mr. Fredun Medhora as the Managing Director of the Company for a further period of five years wef 15.10.2023 to 14.10.2028 The meeting of the board commenced at 03:00 pm and concluded at 07:00 pm08-11-2023
Fredun Pharmaceuticals Ltd - 539730 - Update on board meeting
The Board Meeting to be held on 08/11/2023 has been revised to 08/11/2023 The Board Meeting to be held on 08/11/2023 at 11 am has been revised to 08/11/2023 at 3 pm06-11-2023
Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Intimation for Board Meeting Of The Company On Wednesday, 08Th November, 2023 At 11:00 A.M.
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, 08th November,2023 at 11.00 a.m. to transact inter - alia the following businesses: 1) To discuss, consider and approve Unaudited Financial Results of the Company for the Quarter and half year ended 30th September 2023. 2) To re-appoint Mr. Fredun Nariman Medhora (DIN: 01745348) as the Managing Director for a further term of five years with.31-10-2023
Fredun Pharmaceuticals Ltd - 539730 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate pursuant to Regulation 74(5) of SEBI (Depositories Participants) Regulations, 201809-10-2023
Fredun Pharmaceuticals Ltd - 539730 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Voting Results and Scrutinizer''s Report for the Annual General Meeting held on 29th September, 202330-09-2023
Fredun Pharmaceuticals Ltd - 539730 - Closure of Trading Window
The Trading Window will remain closed for designated persons and their immediate relatives from 1st October, 2023 till 48 hours after the declaration of Unaudited financial results of the Company for the quarter ended 30th September, 202330-09-2023
Fredun Pharmaceuticals Ltd - 539730 - Shareholder Meeting / Postal Ballot-Outcome of AGM
This is to inform you that the 36th Annual General Meeting of Fredun Pharmaceuticals Ltd was held on Friday 29th September,2023 at 09:00 a.m through Video Conferencing/Other Audio Visual means in accordance with the Circulars issued.29-09-2023
Fredun Pharmaceuticals Ltd - 539730 - Reg. 34 (1) Annual Report.
This is in furtherance to the Annual Report for Financial Year 2022-23 submitted to the Stock Exchange on 06th September, 2023 along with the Notice of the 36th Annual General Meeting ("AGM") which is scheduled to be held on Friday, 29th September, 2023 at 09.00 a.m. (IST) via Video Conference/ Other Audio-Visual Means. This is to inform you that certain inadvertent errors were noticed in the Annual Report F.Y. 2022-23 after the same was dispatched to the Shareholders via email dated 06th September, 2023. Accordingly, the Company has revised the Annual Report with the following changes: i) On Page Number 39- The amount of Free Reserves is changed from Rs. 8351.66 Lakhs to Rs. 2041.28 Lakhs. ii) From Page Number 60 to Page Number 67-The Management Discussion and Analysis Report which is annexed as "Annexure V" to the Directors Report is revised.25-09-2023
Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of Board Meeting Dated 22Nd September, 2023
This is to inform you that the Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23, 2022, has done allotment of convertible warrants on preferential basis to Promoters on October 15, 2022. Further, we would like to inform that the Warrant Holders have paid the balance of the consideration aggregating to Rs. 1,42,49,526/- and have applied for exercising their rights for conversion of 19,072 warrants into equivalent number of Equity Shares. Consequently, the Board of Directors in its meeting held on i.e. September 22, 2023 has allotted 19,072 Equity Shares of face value Rs. 10/- each to the warrant holder22-09-2023